World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7560)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

196

WORD

HTML

2622

Figures (1-5)

652

Tables (1-5)

526

Sum=4040

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

324

Download

1316

Sum=1640

Publishing Process of This Article

Item

Count

Browse

308

Download

1321

Sum=1629

Oct 28, 2023 (publication date) through Oct 23, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Hoshimoto A, Tatsuguchi A, Hamakubo R, Nishimoto T, Omori J, Akimoto N, Tanaka S, Fujimori S, Hatori T, Shimizu A, Iwakiri K. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment. World J Gastroenterol 2023; 29(40): 5566-5581 [PMID: 37970475 DOI: 10.3748/wjg.v29.i40.5566]
URL:	https://www.wjgnet.com/1007-9327/full/v29/i40/5566.htm

Number	Citing Articles
1	Xiuping Zhang, Maodong Fu, Zhiyong Li, Feng Shen, Huan Chen, Zhiming Wang, Jingmei Zheng. The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery. Future Science OA 2025; 11(1) doi: 10.1080/20565623.2025.2526993
2	Mohamed Wishahi. Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept. World Journal of Hepatology 2024; 16(4): 490-493 doi: 10.4254/wjh.v16.i4.490 Abstract(548) \| Core Tip(559) \| Full Article(HTML)(2142) \| Full Article with Cover (PDF)-872K(129) \| Audio-323K(10) \| Peer-Review Report-143K(96) \| Answering Reviewers-166K(111) \| Full Article (PDF)-341K(144) \| Full Article (XML)-36K(99) \| Times Cited (1) \| Total Visits (4777) \| Open
3	R.H. Døssing, J.J.A. Bromann, K. Seierøe, E. Høgdall, T.S. Poulsen, J.H.V. Schou, D. Høgdall. The value of MMR characterization and efficacy of checkpoint inhibitor in patients with small-bowel adenocarcinomas: a retrospective real-world cohort study. ESMO Rare Cancers 2025; 4: 100030 doi: 10.1016/j.esmorc.2025.100030
4	Huihui Hu, Man Zhang. PD-1 involvement in CD8+ tumor-infiltrating lymphocytes in patients with colonic-derived peritoneal adenocarcinoma. Brazilian Journal of Medical and Biological Research 2025; 58 doi: 10.1590/1414-431x2025e14467
5	Grigorios Christodoulidis, Marina Nektaria Kouliou, Konstantinos Eleftherios Koumarelas. Immune signature of small bowel adenocarcinoma and the role of tumor microenvironment. World Journal of Gastroenterology 2024; 30(8): 794-798 doi: 10.3748/wjg.v30.i8.794 Abstract(716) \| Core Tip(695) \| Full Article(HTML)(2112) \| Full Article with Cover (PDF)-734K(152) \| Full Article (Word)-114K(15) \| Audio-1212K(7) \| Peer-Review Report-170K(114) \| Answering Reviewers-34K(105) \| Full Article (PDF)-366K(182) \| Full Article (XML)-62K(110) \| Times Cited (1) \| Total Visits (6600) \| Open